Class III, Focal Lupus Nephritis (moderate damage): Some glomeruli are more inflamed with swelling and irritation. Scars may be seen, and the kidneys may not work as well as before. Class IV, Diffuse ...

Over the past dozen years, treatment approaches in lupus nephritis (LN) have changed substantially, and this is reflected in a long-awaited update to the American College of Rheumatology's (ACR ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious than standard therapy alone, according to a new phase 3, placebo ...

Focal proliferative nephritis (class III) without adverse histologic features, such as crescents, fibrinoid necrosis or high chronicity (i.e. chronicity index >3), or adverse clinical features ...

Proliferative lupus nephritis—either focal (Class III) or diffuse (Class IV)— represents the most severe form and has the greatest functional consequences owing to formation of subendothelial ...

Patients were ages 18 to 75 with systemic lupus erythematosus and kidney biopsy-confirmed active class III or IV lupus nephritis, with or without concomitant class V disease.

In addition, 6% shifted to class V, 3% to class II and 6% to a no lupus nephritis classification, defined by lupus podocytopathy and/or focal segmental glomerulosclerosis.

Positive phase III results for Genentech’s Gazyva show superiority to standard therapy alone in people with lupus nephritis. News release. Genentech, Inc. Accessed September 26, 2024.

For lupus nephritis, you will likely start at a dose of 23.7 milligrams (3 tablets) twice a day with a minimum of 8 hours between each of your doses. Ideally, your doses should be taken 12 hours ...

REGENCY [NCT04221477] is a phase III, randomised, double-blind, placebo-controlled, multicentre study investigating the efficacy and safety of Gazyva/Gazyvaro (obinutuzumab) plus standard therapy ...

Source Reference: Sammaritano LR, et al "2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis" Arthritis Rheumatol 2025; DOI: 10. ...

Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...